Editorial board members

Thomas Helmberger

Munich/DE

Thomas Helmberger is a leading expert in interventional oncology, oncologic imaging, and minimally invasive therapies. Since 2007, he has been Director of Radiology, Neuroradiology, and Minimally Invasive Therapy at Munich Klinik Bogenhausen, an Academic Teaching Hospital of the Technical University of Munich (TUM), where he is also an Extraordinary Professor.

His research focuses on oncologic imaging and interventional therapies, including tumor ablation (RFA, MWA, radioembolization, DEB-TACE, HAI), vascular interventions, and advanced imaging strategies for abdominal tumors. 

Mark Burgmans

Leiden/NL

Mark Burgmans is head of Interventional Radiology and vice-chair of the department of Radiology at the Leiden University Medical Center (LUMC) in the Netherlands. He is also a staff member at the Technical University in Delft. Dr. Burgmans was trained as a radiologist at the University Medical Center Utrecht and completed a PhD on minimally invasive liver-directed therapies at the Leiden University. He is a member of the ESR Sustainability Committee, IASIOS council, Scientific Committee of the Dutch Society of Interventional Radiology, Clinical Audit Board of the Dutch Hepatobiliary Audit, Dutch Benign Liver Tumor Group and ECIO 2025 scientific committee. Dr. Burgmans is the former President of the Dutch Society of Interventional Radiology. He is the head of the Interventional Radiology Research (IR2) at the LUMC, which focuses on research in interventional oncology. The main research lines of the group include liver tumor ablation, AI- and machine learning-based outcome prediction, navigation devices, percutaneous hepatic perfusion and sustainability in IR.

Lynn J. Savic

Berlin/DE

Lynn J. Savic is an Assistant Professor of Radiology at Charité in Berlin, specializing in interventional radiology. She is also a Fellow of the Clinician Scientist Program at the Berlin Institute of Health and leads the Minimally Invasive Tumor Therapies (MITT) Lab at Charité. She completed her doctoral training at Johns Hopkins and a postdoctoral fellowship at the Yale School of Medicine.  
The MITT Lab's research spans basic science, translational studies in animal tumor models, and prospective clinical trials, incorporating biobanking and biomaterial analysis to enhance loco-regional therapies such as transarterial chemoembolization and ablation. Dr. Savic’s work further focuses on developing advanced multimodal imaging biomarkers for assessing tumor susceptibility and treatment response in hepatocellular carcinoma (HCC).
In addition to her research, Dr. Savic is actively involved in academic leadership, serving on the RSNA Annual Meeting Program Planning Committee and the SIO Research Committee.

Roberto Iezzi

Rome/IT

Roberto Iezzi serves as Associate Professor of Diagnostic and Interventional Radiology at the Medical School of Catholic University of Rome and Director of Emergency and Interventional Radiology at Fondazione Policlinico A. Gemelli - IRCCS of Rome (IASIOS Accreditated Center). He graduated from "G. D'Annunzio" University in Chieti (ITALY) and became a full Radiologist in 2003. He is author or coauthor of a number of publications (>200 IF published articles), abstracts and book chapters. He is an Advisory Board Member of Next Research, IASIOS Council Member, and Deputy Member of CIRSE's Education Online Committee.

His research and clinical practice focus upon interventional oncology (ablative and intra-arterial techniques), as well as extravascular and endovascular minimally invasive therapies.

Miyuki Sone

Tokyo/JP

Miyuki Sone, MD, is the head of the Interventional Radiology Center and a consultant diagnostic radiologist at the National Cancer Center Hospital in Japan. She earned her medical degree from Iwate Medical University and later served as an assistant professor. She is a member of the Executive Board Committee of the Japanese Society of Interventional Radiology and the chair of Japan Interventional Radiology in Oncology Study Group. She has a longstanding interest in interventional radiology (IR), clinical trials for IR, and abdominal imaging.

Sanja Stojanovic

Novi Sad/RS

Sanja Stojanovic is a full term professor at the position of Head of Board of Radiology at Medical Faculty in Novi Sad and the Head of Department of Interventional Radiology at the University Clinical Center of Vojvodina. She was awarded with CIRSE grant and, since 2010, is one of the pioneers of Oncology Interventions in Serbia and very active in organizing educative programmes and radiology workshops.

Her focus of interest are ablative and intra-arterial therapies and CT/MR imaging.

Arndt Vogl

Toronto/CA

Arndt Vogel is a full professor at the University of Toronto, Canada. He is appointed as the Longo Family Chair in Liver Cancer Research and is leading a multi-pronged research program in basic and clinical science at the Toronto General Hospital and the Princess Margarete Cancer Center. Before joining UNH, he worked as senior consultant at Hannover Medical School for more than 20 years and still holds a research position there.He is author or co-author of more than 330 articles published in peer-reviewed journals including Lancet, Lancet Oncology, Cancer Cell, and Gastroenterology among others. He is member of societies including ESMO, ASCO, and EASL. He is member and chairman of Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany.

His scientific focus is the translational and clinical research in gastrointestinal cancer.

Julius Chapiro
New Haven/US

Julius Chapiro is an Associate Professor in Radiology, Digestive Diseases (Hepatology) and in Biomedical Engineering, Principal Investigator of the Yale Interventional Oncology Research Lab and Director of the Center for Minimally Invasive Therapies.

His research focuses on developing new quantitative imaging biomarkers for the diagnosis, characterization, and therapeutic management of liver cancer. His translational research portfolio includes the development of novel embolic agents as well as the application of artificial intelligence solutions for the management of liver cancer. His basic research interest mainly focuses on developing new tools to characterize the tumor microenvironment and the immune system in the setting of loco-regional, image-guided therapies of liver cancer.

Bin-Yan Zhong
Hangzhou/CN

Bin-Yan Zhong is currently an attending physician as well as a senior researcher at Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences. He is also the office director of the center of Interventional Radiology at Zhejiang Cancer Hospital. His main interest and expertise is in the field of interventional therapies and systemic therapies for hepatobiliary malignancies.